9312548
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects

Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects
type: Information Content Entity
type: Thing
type: Document
related by: 9312549
type: Continuant
type: Entity
type: Generically Dependent Continuant
type: Article
type: Academic Article
related by: 9312548
language: Inglese
most specific type: Academic Article

Document
type: Class

9312549
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects

Academic Article
type: Class

Continuant
type: Class

Inglese
type: Language

Entity
type: Class

Generically Dependent Continuant
type: Class

individual
rights: termsOfUse
date: 2026-08-26T16:56:22
publisher: Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects
type: Document
label: RDF description of Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects - http://irises.unibs.it/resource/item/104800

Article
type: Class

Information Content Entity
type: Class